CAR-T therapy, an increasing promising immunotherapy approach, is gaining significant momentum in the field of cancer treatment. It revolves around the genetic modification of T cells by introducing chimeric antigen receptors (CARs) to enhance their specificity and anti-tumor activity. CAR molecules are composed of several key components, including a signal peptide, an antibody-derived single-chain variable fragment (scFv), a hinge region, a transmembrane domain, a co-stimulatory molecule, and a CD3ζ signaling domain.
Figure 1.CAR molecular structure[1]
AcceGen offers CAR design and construction services, as well as other specialized CAR strategies, to support research in combating cancer. Our services include biomarker identification, CAR generation, in vitro and in vivo assays, and clinical trials. With AcceGen’s expertise, you can access comprehensive support at various stages of CAR-T studies, accommodating different starting materials and research needs.
Application
Reference
[1]. Zhang, C., Liu, J., Zhong, J.F. et al. Engineering CAR-T cells. Biomark Res 5, 22 (2017)